Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenici...

2023-09-21 18:05 2933

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2023-08-25 19:37 3161

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercializatio...

2023-08-11 08:00 4011

Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusiv...

2023-07-18 08:30 3006

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has ...

2023-07-17 08:30 3555

Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor...

2023-06-01 10:09 4108

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 mo...

2023-05-26 09:41 3953

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-05-23 17:25 3471

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibod...

2023-05-18 11:53 3905

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody...

2023-05-18 02:47 3554

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-05-17 08:30 3954

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-04-27 08:30 3727

Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting

* Five posters showcased progress with multiple preclinical and clinical programs, includingATG-0...

2023-04-17 20:22 3129

Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia

* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugat...

2023-03-29 08:30 3439

Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation

SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-03-28 21:40 3401

Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting

– Five posters will showcase progress with multiple preclinical and clinical programs, including t...

2023-03-20 15:20 2782

Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China

- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate...

2023-03-14 12:29 3671

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-01-03 14:10 2858

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's ant...

2022-12-27 08:30 4085

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2022-12-23 08:30 4354